WuXi Biologics
Offering End-to-End Solutions
As more ADC modalities advance from the preclinical candidate (PCC) stage into the Chemistry Manufacturing Control (CMC) development stage, process development (PD) scientists inevitably face tremendous challenges such as the need for larger-scale and more consistent CMC processes. At the Bioconjugation Process Development (BCPD) department of XCD, experienced experts specialized in consistent and scalable conjugation and purification have delivered more than a hundred processes within aggressive timelines to support IND filing or to conduct process characterization (PC) activities for programs working towards a BLA submission. This poster will present case studies of the solutions established for challenging process development projects.
This scientific poster was originally presented during the 2024 World ADC Conference in London
Discuss This Poster
To discuss the data in this poster, please complete the form on the following page to connect with our experts.
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?